Anavex Life Sciences Corp (AVXL)

[catdaddy]

Someone out there disagrees, Doc:

Concise Refutation + Bullet-Point Summary
Key Takeaway: The bear case is overstated. JPAD delivered a large, pre-specified cognition signal in early AD with supportive biomarkers and OLE data — a credible package for conditional approval.
Bullet-Point Summary
• S1R WT subgroup was pre-specified (not post-hoc) ? -2.32 points ADAS-Cog13 (P=0.015) in ~70% of patients
• COL24A1 WT (ABCLEAR2/3, Sep 2025) ? -4.74 points ADAS-Cog13 (P=0.0004) in another ~70% subgroup
• OLE (despite 70% dropout) ? -12.78 points vs ADNI at Year 3 (external control)
• Assumed SD 4.5 was optimistic but defensible for early AD; observed SD ~8 but observed effect 2.0–2.3 points > planned 1.5 ? actual power ~75–85% overall, ~70% in S1R WT
• CDR-SB significant (-0.456, P=0.0175); ADCS-ADL miss is typical in early AD (ceiling effect, same as lecanemab)
• Oral, no ARIA, upstream mechanism ? strong differentiation vs anti-amyloid mAbs
• Ongoing CHMP re-examination + requested FDA meeting (Nov 2025) ? realistic path to conditional approval
Bottom line: Far from “laughable” — the data package is among the stronger oral/small-molecule AD datasets seen to date.